Chirgwin, J; Sun, Z; Smith, I; Price, K N; Thürlimann, B; Ejlertsen, B; Bonnefoi, H; Regan, M M; Goldhirsch, A; Coates, A S (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131(1):295-306.
Regan, M M; Neven, P; Giobbie-Hurder, A; Goldhirsch, A; Ejlertsen, B; Mauriac, L; Forbes, J F; Smith, I; Láng, I; Wardley, A; Rabaglio, M; Price, K N; Gelber, R D; Coates, A S; Thürlimann, B (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncology, 12(12):1101-1108.
Regan, M M; Price, K N; Giobbie-Hurder, A; Thürlimann, B; Gelber, R D (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Research, 13(3):209.
Mouridsen, H; Giobbie-Hurder, A; Goldhirsch, A; Thürlimann, B; Paridaens, R; Smith, I; Mauriac, L; Forbes, J F; Price, K N; Regan, M M; Gelber, R D; Coates, A S (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine, 361(8):766-776.
Viale, G; Regan, M M; Maiorano, E; Stahel, R A (2008). Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Journal of Clinical Oncology, 26(9):1404-1410.
Regan, M M; Pagani, O; Walley, B; et al; Stahel, R A (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of Oncology, 19(7):1231-1241.
Viale, G; Giobbie-Hurder, A; Regan, M M; Stahel, R A (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. Journal of Clinical Oncology, 26(34):5569-5575.
Ravaioli, A; Monti, F; Regan, M M; Maffini, F; Mastropasqua, M G; Spataro, V; Castiglione-Gertsch, M; Panzini, I; Gianni, L; Goldhirsch, A; Coates, A; Price, K N; Gusterson, B A; Viale, G (2008). p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of Oncology, 19(4):660-668.